Pfizer announced that it has received Fast Track status from the FDA for its developing gene therapy - PF-06939926, for the treatment of Duchenne muscular dystrophy. The company has now accelerated its work to begin the planned Phase 3 program. It is estimated that in the USA about 10 -12 thousand people suffer from MDD.